A switch from ER-driven growth to involvement of HER receptor-driven growth has been described for antiestrogen-resistant breast cancer cells (41–44), and model systems have indicated that resistance to AIs may involve cross-talk between ER and growth factor signaling pathways, and ligand-independent activation of ER (27, 45–47). Here, ESR1 is linked to breast cancer.